touchIMMUNOLOGY joins Professor Neil Gittoes (University of Birmingham, UK), Chair of the Royal Osteoporosis Society, at WCO21 to discuss the mission of the society and hopes for the current initiatives to forward osteoporosis research.
1. Could you tell us a little about the health burden of osteoporosis in the UK? (00:19-02:30)
2. What are the aims of the research roadmap that the Royal Osteoporosis Society has produced? (02:30-04:00)
3. Who has been involved in the development of the Research Roadmap? (04:00-05:40)
4. Could you give us an overview of the research priorities? (05:40-08:07)
Disclosures: Neil Gittoes has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the WCO21 Annual Meeting.
Share this Video
Related Videos In Bone Disorders
Andrea R Genazzani, WCO IOF-ESCEO 2022: Hormone Replacement Therapy for Bone Loss Prevention Post Menopause (Part 2)
It was a pleasure to talk with Dr. Andrea R Genazzani (International Society of Gynecological Endocrinology and European Society of Gynecology) to find out when, in whom and for how long hormone replacement therapy should be administered for bone loss prevention post-menopause. ‘Hormone Replacement Therapy in post-menopause for bone loss prevention: when, how and for […]
Andrea R. Genazzani, WCO IOF-ESCEO 2022: Hormone Replacement Therapy for Bone Loss Prevention Post Menopause (Part 1)
touchENDOCRINOLOGY were delighted to catch up with Dr. Andrea R. Genazzani (International Society of Gynecological Endocrinology and European Society of Gynecology) to discuss the health burden of osteoporosis in post-menopausal women and how HRT could be used as a prevention strategy. ‘Hormone Replacement Therapy in post-menopause for bone loss prevention: when, how and for how […]
Michael R. McClung, WCO IOF-ESCEO 2022: Therapeutic Updates in Osteoporosis
We were delighted to talk with Dr Michael R. McClung (Oregon Osteoporosis Center, Portland, OR, USA) around the current unmet needs and standard of care for osteoporosis and the therapeutic targets currently being investigated that could lead to new drug approvals. ‘Can we expect new chemical entities for the management of osteoporosis in the coming […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!